Pulmonary fibrosis results from chronic lung injury triggering aberrant repair: epithelial damage, fibroblast proliferation, and excessive collagen deposition. Idiopathic pulmonary fibrosis (IPF) shows usual interstitial pneumonia (UIP) pattern with patchy fibrosis and architectural distortion.
Distinguish usual interstitial pneumonia (IPF) from other patterns (nonspecific interstitial, organizing pneumonia). Understand triggers: occupational exposure (silicosis, asbestos), autoimmunity (scleroderma), and drugs. Use HRCT and FVC decline to assess progression.
Pulmonary fibrosis is not always progressive—some patterns are stable or improve with treatment. UIP pattern on imaging does not prove IPF; other conditions can mimic it.
Pulmonary fibrosis is fundamentally a disease of aberrant wound healing. To understand it, connect it to your prerequisites: chronic inflammation sets up a persistent injury-repair cycle, and myofibroblast differentiation is the cellular engine that converts that cycle into permanent structural damage. Normally, alveolar epithelial injury triggers a healing cascade that resolves cleanly — inflammation clears the debris, fibroblasts deposit a temporary collagen scaffold, and epithelial cells repopulate the alveolar surface. In fibrotic disease, this process fails to terminate: the inflammatory signal persists, fibroblasts differentiate into myofibroblasts (expressing α-smooth muscle actin, driven by TGF-β), and those myofibroblasts continuously deposit type I and III collagen. The result is replacement of functional, gas-exchanging alveolar tissue with dense, inelastic scar tissue.
The mechanical consequence is a restrictive ventilatory defect: lung compliance falls (the lung is stiff and hard to expand), total lung capacity decreases, and the thickened alveolar-capillary membrane impairs gas diffusion — the diffusing capacity for carbon monoxide (DLCO) declines even before obvious spirometric restriction appears. Patients present with progressive dyspnea on exertion and a dry, non-productive cough. Unlike obstructive diseases, air moves freely once the lung is inflated; the problem is getting it inflated at all.
Idiopathic pulmonary fibrosis (IPF) is the most aggressive form, defined by the usual interstitial pneumonia (UIP) pattern on high-resolution CT: heterogeneous, predominantly basal and subpleural fibrosis with honeycombing (destroyed, cystic airspaces) and traction bronchiectasis. "Usual" here means the most common histologic pattern among IIPs — not "usual" in the everyday sense. The UIP pattern on HRCT combined with appropriate clinical context (age >60, male predominance, occupational or smoking history) can establish IPF without surgical biopsy. Other interstitial patterns — nonspecific interstitial pneumonia (NSIP), organizing pneumonia — have better prognoses and may respond to immunosuppression, which is why pattern recognition matters.
The fibrogenic pathway is dominated by TGF-β1: released by damaged alveolar epithelial cells and macrophages, it drives myofibroblast differentiation and suppresses epithelial regeneration. Anti-fibrotic drugs (pirfenidone, nintedanib) reduce the rate of FVC decline in IPF, but do not reverse established fibrosis. This reflects the fundamental problem: once collagen is deposited and architectural distortion has occurred, there is no mechanism to regenerate alveolar structure. Prevention and early detection — by recognizing the restrictive pattern, the bibasilar crackles on exam, and the HRCT abnormalities — are therefore more impactful than any current pharmacologic intervention.